In the phase 3 TRIUMPH-1 trial involving patients with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. Full trial results: nej.md/4ycgSHz

ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." The graph shows effect of retatrutide on body weight. The trial name, TRIUMPH-1, is in parentheses after the title. The NEJM identity sits at the bottom.
Dra. Paola Harwicz retweeted
💉 TRIUMPH-2: retatrutida en obesidad + DM2, 80 semanas. @TheLancet #EASD2026
Peso −18,8% con 12 mg vs −5,1% placebo.
La HbA1c baja igual con 4, 9 o 12 mg (~−1,4%). ¿Dosis máxima para todos? Quizá no 🎯
Y menos retinopatía que con placebo 👀
⚠️ No aprobada por el momento
🖇️
thelancet.com/journals/lance…
Dra. Paola Harwicz retweeted
Congreso #Cardiometabolismo25
Un honor ser parte de los embajadores digitales 😀
Te contaremos todas las novedades de este gran evento científico ✍🏾
🗓️13-14 Agosto, Buenos Aires 🇦🇷
sac.org.ar/sac-eventos/congr…
@SAC_54 @SACcardiometab1
Dra. Paola Harwicz retweeted
Ya falta muy poco para el Congreso CardioMetabolismo.25
🗓️13-14 de agosto, La rural, Buenos Aires
🙌🏼Te esperamos !!!!
@SACcardiometab1 @SAC_54
Más información sac.org.ar/sac-eventos/congr…
Dra. Paola Harwicz retweeted
"Relevamiento Nacional sobre el Manejo de la Obesidad en el Consultorio de Cardiología en Argentina"
redcap.link/3sxibith
Si eres Cardiologo de Argentina, nos interesa conocer tu opinión, la encuesta es anónima y no te llevará mas de 4 minutos responderla 🙏
@SACcardiometab1
Dra. Paola Harwicz retweeted
CAFÉ ☕️ Y RIESGO CARDIOVASCULAR 🫀
Estudios observacionales encontraron que el consumo moderado de café tiene asociación con:
⬇️Riesgo de HTA, Diabetes, stroke, enf. coronaria y FA
⬆️Riesgo de extrasístoles ventriculares y dislipemia
#Cafe
academic.oup.com/eurheartj/a…
Dra. Paola Harwicz retweeted
🚨 Coming soon in @ATHjournal !
A powerful new review explores the link between adipose tissue dysfunction and atherosclerosis, shedding light on innovative therapies.
This comprehensive review explores the complex interplay between adipose tissue dysfunction and atherosclerosis, emphasizing the role of chronic inflammation, oxidative stress, and dysregulated adipokine signaling. A major section of the article highlights the therapeutic potential of SGLT2 inhibitors (SGLT2i) beyond glycemic control.
Key Points on SGLT2i and Cardiovascular Benefits:
1⃣Anti-inflammatory action: SGLT2i reduce inflammatory cytokines in adipose tissue, mitigating one of the root causes of atherosclerosis.
2⃣Improved adipose tissue function: These agents promote the browning of white adipose tissue and enhance mitochondrial efficiency, leading to better metabolic profiles.
3⃣Cardiovascular outcomes: The article reinforces that SGLT2i significantly lower the incidence of major adverse cardiovascular events (MACE), heart failure hospitalization, and cardiovascular mortality in patients with type 2 diabetes and high CV risk.
4⃣Mechanistic insights: The cardiovascular protection may be partially attributed to SGLT2i’s effects on endothelial function, blood pressure reduction, and decreased arterial stiffness—benefits that extend beyond glucose lowering.
Conclusion:
The article underscores the evolving role of SGLT2 inhibitors as a cornerstone in the prevention of atherosclerotic complications, particularly in patients with metabolic syndrome or type 2 diabetes, and emphasizes their value in addressing the inflammatory and metabolic derangements of dysfunctional adipose tissue.
@society_eas
atherosclerosis-journal.com/…
Dra. Paola Harwicz retweeted
ESTRATIFICACIÓN DE RIESGO Y MANEJO SEGÚN ESTADÍO DE ATEROSCLEROSIS
-Cuándo vemos la placa calcificada en un estudio de imagen ya llegamos demasiado tarde🙄
-50% tiene eventos isquémicos sin placa, o con placa pero sin estenosis 😖
academic.oup.com/cardiovascr…
Dra. Paola Harwicz retweeted
One of the worst things for science is when a leading journal like @JACCJournals publishes a manuscript so devoid of ethical and scientific rigor.
The responsible action would be to retract it and issue a public apology.
Anything less is a disservice to the medical community.
🚨 KETO-CTA: A Teachable Moment in Scientific Transparency
- - -
What happens when a highly publicized study FAILS to report its primary outcome?
The KETO-CTA study, designed to evaluate the impact of diet-induced hypercholesterolemia on coronary plaque progression, has sparked interest—and concern. Despite preregistering % change in non-calcified plaque volume (ΔNCPV) as the primary endpoint (see image below), the investigators did not report this outcome directly in the manuscript. Instead, results appeared later...in a social media meme.
🔍 Why it matters:
Non-calcified plaque progression is not a trivial metric—it’s the most relevant measure of early atherosclerotic risk. In KETO-CTA, ΔNCPV was +18.8 mm³ in one year (according to the lead investigator--see below), a rate typically associated with much higher-risk cohorts (e.g., familial hypercholesterolemia or diabetes). This was a study of supposedly "low-risk" individuals.
📉 Additional limitations include:
🔹 Short follow-up (1 year): Too brief to reliably detect meaningful progression in low-risk populations. Most longitudinal plaque imaging studies span 3–6 years.
🔹 Lack of control group: No comparator arm to contextualize imaging findings or isolate effects of diet-induced hypercholesterolemia.
🔹 Historical controls misapplied: Cross-study comparisons without accounting for differences in baseline risk, imaging protocols, or statistical methods.
🧠 This isn’t just about one study.
When primary outcomes vanish from manuscripts, it erodes trust. When clinical implications are downplayed, we risk misleading patients. The duty to report results transparently isn't optional—it’s foundational to scientific integrity.
Let’s be clear: ketogenic diets may offer benefits in select cases. But studies evaluating their cardiometabolic effects must be held to the same rigorous standards applied to all clinical research. In this case, the investigators appear to have fallen short—and possibly engaged in selective or misleading reporting to obscure unfavorable outcomes.
📣 We need better, not louder. We need data, not dodges. Most importantly, we need to treat scientific integrity as non-negotiable.
STUDY: jacc.org/doi/10.1016/j.jacad… #EvidenceBasedMedicine #KetoCTA #Cardiology #ResearchEthics #ScientificIntegrity #PreventiveCardiology
Dra. Paola Harwicz retweeted
🚨 KETO-CTA: A Teachable Moment in Scientific Transparency
- - -
What happens when a highly publicized study FAILS to report its primary outcome?
The KETO-CTA study, designed to evaluate the impact of diet-induced hypercholesterolemia on coronary plaque progression, has sparked interest—and concern. Despite preregistering % change in non-calcified plaque volume (ΔNCPV) as the primary endpoint (see image below), the investigators did not report this outcome directly in the manuscript. Instead, results appeared later...in a social media meme.
🔍 Why it matters:
Non-calcified plaque progression is not a trivial metric—it’s the most relevant measure of early atherosclerotic risk. In KETO-CTA, ΔNCPV was +18.8 mm³ in one year (according to the lead investigator--see below), a rate typically associated with much higher-risk cohorts (e.g., familial hypercholesterolemia or diabetes). This was a study of supposedly "low-risk" individuals.
📉 Additional limitations include:
🔹 Short follow-up (1 year): Too brief to reliably detect meaningful progression in low-risk populations. Most longitudinal plaque imaging studies span 3–6 years.
🔹 Lack of control group: No comparator arm to contextualize imaging findings or isolate effects of diet-induced hypercholesterolemia.
🔹 Historical controls misapplied: Cross-study comparisons without accounting for differences in baseline risk, imaging protocols, or statistical methods.
🧠 This isn’t just about one study.
When primary outcomes vanish from manuscripts, it erodes trust. When clinical implications are downplayed, we risk misleading patients. The duty to report results transparently isn't optional—it’s foundational to scientific integrity.
Let’s be clear: ketogenic diets may offer benefits in select cases. But studies evaluating their cardiometabolic effects must be held to the same rigorous standards applied to all clinical research. In this case, the investigators appear to have fallen short—and possibly engaged in selective or misleading reporting to obscure unfavorable outcomes.
📣 We need better, not louder. We need data, not dodges. Most importantly, we need to treat scientific integrity as non-negotiable.
STUDY: jacc.org/doi/10.1016/j.jacad… #EvidenceBasedMedicine #KetoCTA #Cardiology #ResearchEthics #ScientificIntegrity #PreventiveCardiology
Dra. Paola Harwicz retweeted
#ACC25 STRIDE trial
#Semaglutide en Enf vascular periférica
Sintomática y DBT2
🔴Estudio multicentrico 792👥
🔴Sema mejoró el punto final primario en ⬆️caminata 6 min a las 52 sem y los PF secundarios
@ACCinTouch
thelancet.com/journals/lance…
Dra. Paola Harwicz retweeted
#ACC25 SOUL trial
🔴RCT 9656 👥 DBT2 y Enf CV y/o renal
🔴#Semaglutide #oral 🆚 placebo demostró ⬇️del punto final 3 MACE NNT 50
🔴Primer GLP1a oral con beneficio CV demostrado
Dra. Paola Harwicz retweeted
👉 Overweight, obesity, and CVD in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry
☝️ The data from 6275 children and 29 265 adults provide evidence that obesity is common in those with HeFH and is associated with a more severe hyperlipidaemia phenotype and greater likelihood of ASCVD from childhood. Given their already augmented risk of ASCVD, patients with FH should be prioritized from the point of FH diagnosis for intensive lifestyle management aimed at maintaining a healthy weight, to reduce their lifetime risk of CVD events. A holistic approach, integrating body weight management with LDL-C-lowering treatments, should be used to improve cardiovascular outcomes in people with FH
Another great publication from the @fhscglobal led by @ProfKausikRay
🔓Open Access
academic.oup.com/eurheartj/a…
@society_eas
@ehj_ed
@escardio
Dra. Paola Harwicz retweeted
🚨Se publicaron las nuevas guías de cuidado de la diabetes de la Asociación Americana de Diabetes 2025.
👉🏽¿Qué recomendaciones dan en relación con alimentación y nutrición? ¿Qué dijeron sobre el "peligrosísimo" pan?
Va hilo🧵...
Dra. Paola Harwicz retweeted
Viernes a la noche, Clase de #Diabetes
Diplomado UCA - SAC 💪🏼
@schiavonemj
Dra. Paola Harwicz retweeted
Excelente webinar de ayer en los miércoles son de @SLANH_ . Hablando precisamente de obesidad y riesgo cardio renal . Gracias a los excelentes conferencistas 🇦🇷🇲🇽y moderador . A propósito del día mundial de la Obesidad . @SLANHJoven . @tomaspjmz @DeNefrologos @gustavo_lavenia
Dra. Paola Harwicz retweeted
👉Dietary fat quality, plasma atherogenic lipoproteins, and atherosclerotic cardiovascular disease:
An overview of the rationale for the dietary recommendations for fat intake
👏Evidence Based Medicine
☝️Dietary fat quality is the main environmental determinant of plasma LDL-C.
☝️Fat quality affects the risk of ASCVD risk mainly by modifying the plasma LDL-C.
☝️Main message: within an otherwise healthy dietary pattern, switching from the consumption of foods containing unhealthy fats (SFAs, TFAs and cholesterol) to the consumption of foods containing healthy fats (MUFAs, n6-PUFAs and n3-PUFAs) will prevent or improve dyslipidemia, reduce the cholesterol burden and rate of atherosclerosis progression, and reduce the risk of clinical ASCVD
@society_eas
@ATHjournal
@jacobjchr
doi.org/10.1016/j.atheroscle… – at Mar del Plata, Argentina
Dra. Paola Harwicz retweeted
Sin palabras con los resultados del #SELECT trial:
✅ Muerte CV+IM no fatal+ictus no fatal
✅ mortalidad por cualquier causa
✅ IM no fatal
✅ Nueva revascularización
Call de action ‼️
Dra. Paola Harwicz retweeted
🗣️Hace apenas 3 días finalizó el Congreso Europeo de Diabetes #EASD2023…
👉🏻 Después de muchos años sin novedades en los criterios dignósticos de #diabetes…
El gran Jakko Toumilehto trajo un planteo #disruptivo:💥
🆕Utilizar la glucosa posprandial a la hora de la sobrecarga! – at Concordia, Argentina
Dra. Paola Harwicz retweeted
Identify the #CVD 💔 risk factors!
❌ High blood pressure
❌ High cholesterol
❌ Smoking
❌ Diabetes
❌ Obesity
❌ Unhealthy diet
❌ Family history
When we understand these ⬆️ we can better assess, control and monitor heart health. #UseHeart #WorldHeartDay













































